KLK2-targeted immunotherapies present a promising opportunity in prostate cancer treatment. Elevated KLK2 in tumors and its surface expression make it an accessible target. Success in preclinical ...
The hold follows the company’s earlier voluntary pause in late February 2026, triggered by reversible cardiac observations seen at supratherapeutic doses in a healthy volunteer study. ・Aardvark now ...
Background Cardiovascular disease and osteoarthritis (OA) share risk factors, but the link between comprehensive ...